Insulet Corporation (PODD) — Comparison of Productivity to Peers
Insulet Corporation's Productivity vs Peers Comparison
Table 1: Market Cap, Revenue per Employee, Income per Employee for the 12 Months period ended in Q3 2025
| COMPANY NAME TICKER |
MARKET CAP (Millions $) |
REVENUE / EMPLOYEE ($) in 12 months |
INCOME / EMPLOYEE ($) in 12 months |
|---|---|---|---|
|
Insulet Corporation
PODD |
21,521 | 840,633 | 82,067 |
|
Titan Pharmaceuticals Inc
TTNP |
5 | - | -200,357 |
|
Embecta Corp
EMBC |
688 | 266,947 | 19,357 |
|
Medtronic Plc
MDT |
130,513 | 347,580 | 47,920 |
|
Dexcom Inc
DXCM |
26,583 | 470,313 | 75,073 |
|
Tandem Diabetes Care Inc
TNDM |
1,401 | 420,336 | -72,590 |
|
Abbott Laboratories
ABT |
218,093 | 384,588 | 122,605 |
|
Johnson and Johnson
JNJ |
489,290 | 685,632 | 186,897 |
|
Nemaura Medical Inc
NMRD |
0 | - | -343,578 |
|
Vivani Medical Inc
VANI |
84 | - | - |
|
Modular Medical Inc
MODD |
17 | - | -475,350 |
|
Semler Scientific inc
SMLR |
336 | 1,192,161 | 1,559,323 |
|
Myomo Inc
MYO |
43 | 969,507 | -286,191 |
|
Universal Biosensors Inc
UBI |
0 | 60,404 | -200,638 |
| SUBTOTAL | 867,053 | 486,540 | 121,948 |
What this table shows: Productivity metrics illustrate how effectively a company converts workforce and capital into value. Higher Revenue per Employee and Net Income per Employee generally reflect stronger operating efficiency and business scalability. First row shows Company's Productivity, followed by it's corporate peers. Click any company name in the table to view its complete financial analysis and comparison.
Insulet Corporation's Financial Strength vs Peers Comparison
Table 2: Quick Ratio, Working Capital, Debt/Equity, Asset Turnover
| COMPANY NAME TICKER |
QUICK (Ratio) |
WORKING CAPITAL (Ratio) |
DEBT / EQUITY (Ratio) |
ASSET TURNOVER (Ratio) |
|---|---|---|---|---|
|
Insulet Corporation PODD |
- | 3.09 | 1.02 | 0.77 |
| Titan Pharmaceuticals Inc
TTNP |
7.86 | 8.40 | - | - |
| Embecta Corp
EMBC |
0.80 | 2.40 | - | 0.96 |
| Medtronic Plc
MDT |
0.72 | 2.03 | 0.58 | 0.38 |
| Dexcom Inc
DXCM |
0.36 | 1.51 | 1.01 | 0.64 |
| Tandem Diabetes Care Inc
TNDM |
1.53 | 2.63 | 1.72 | 1.08 |
| Abbott Laboratories
ABT |
0.65 | 1.70 | 0.45 | 0.60 |
| Johnson and Johnson
JNJ |
0.47 | 1.11 | 0.60 | 0.49 |
| Nemaura Medical Inc
NMRD |
0.13 | 0.38 | - | - |
| Vivani Medical Inc
VANI |
1.58 | 1.87 | - | - |
| Modular Medical Inc
MODD |
2.89 | 4.04 | - | - |
| Semler Scientific inc
SMLR |
0.41 | 1.10 | 0.25 | 0.09 |
| Myomo Inc
MYO |
1.74 | 2.68 | 0.06 | 1.05 |
| Universal Biosensors Inc
UBI |
2.26 | 3.69 | 0.01 | 0.15 |
| SUBTOTAL | 0.54 | 1.37 | 0.58 | 0.49 |
What this table shows: Financial Strength ratios measure short-term liquidity (Quick Ratio, Working Capital), leverage (Debt/Equity), and operational utilization (Asset Turnover). These indicators highlight how well management allocates resources and maintains financial stability.
Insulet Corporation's Underlying Financial Totals (Revenue, Income, Employees) vs Peers Comparison
Table 3: Revenue (TTM), Net Income (TTM), Net Margin, Employees, ending Q3 2025
| COMPANY NAME TICKER |
REVENUE (TTM) Millions $ |
NET INCOME (TTM) Millions $ |
NET MARGIN (%) |
NUMBER OF EMPLOYEES |
|---|---|---|---|---|
| Insulet Corporation PODD |
2,521.9 | 246.2 | 9.76% | 3,000 |
| Titan Pharmaceuticals Inc TTNP |
- | -3 | - | 14 |
| Embecta Corp EMBC |
1,080 | 78 | 7.25% | 4,045 |
| Medtronic Plc MDT |
34,758 | 4,792 | 13.79% | 100,000 |
| Dexcom Inc DXCM |
4,515 | 721 | 15.96% | 9,600 |
| Tandem Diabetes Care Inc TNDM |
1,009 | -174 | -17.27% | 2,400 |
| Abbott Laboratories ABT |
43,843 | 13,977 | 31.88% | 114,000 |
| Johnson and Johnson JNJ |
92,149 | 25,119 | 27.26% | 134,400 |
| Nemaura Medical Inc NMRD |
- | -11 | - | 31 |
| Vivani Medical Inc VANI |
- | -26 | - | - |
| Modular Medical Inc MODD |
- | -19 | - | 40 |
| Semler Scientific inc SMLR |
37 | 48 | 130.8% | 31 |
| Myomo Inc MYO |
41 | -12 | -29.52% | 42 |
| Universal Biosensors Inc UBI |
5 | -17 | -332.16% | 87 |
| SUBTOTAL | 177,436 | 44,473 | 25.06% | 364,690 |
What this table shows: These totals provide the raw financial fundamentals behind the productivity, Revenue and Income per Employee ratios above. Revenue, Net Income, and Employee counts reflect the company’s scale, profitability, and workforce size. TTM refers to trailing twelve months.
Methodology & Data Source: Market Capitalization is computed from the latest available share price (delayed up to 15 minutes, depending on exchange rules) multiplied by the company’s diluted share count as reported in its filings. Revenue and Net Income figures used to calculate Revenue per Employee and Net Income per Employee are sourced directly from quarterly and annual financial statements submitted to the U.S. Securities and Exchange Commission (SEC). Employee counts are taken from the most recent Form 10-K or 10-Q disclosure and may be updated by companies in subsequent SEC submissions. All fundamentals are processed through CSIMarket.com’s XBRL normalization pipeline, which standardizes reported values across all issuers and periods.
Data lineage: SEC Filings → XBRL Extraction → CSIMarket Normalization → Productivity Metrics.
This table is one of the productivity comparisons available for
Insulet Corporation. Across CSIMarket, we provide
nine related comparison tables showing how Insulet Corporation performs against its
Peers, including additional breakdowns visible through our main navigation bar under:
Stocks → Peers.
This page compares Insulet Corporation to its Peers based on Productivity (Market Cap, Revenue per Employee, and Net Income per Employee).
• For a deeper productivity comparison against its industry peers, visit
Insulet Corporation Productivity vs. Industry
• To review historical productivity trends for this company, including long-term changes in Revenue per Employee and Net Income per Employee, visit
Insulet Corporation Productivity History
Page last updated:
CSIMarket data powering this analysis is available across multiple delivery channels:
• Data Downloads (CSV / Excel)
• API & Programmatic Data Access
• Enterprise Data Licensing
• AI Training & Model Development License
• Marketplace Distribution Options
All CSIMarket datasets are designed for analytical workflows, financial modeling, academic research,
and AI/ML applications requiring normalized, reliable, and longitudinal financial time series.
To download the tables, please subscribe.